A dose‐finding study of once‐daily oral telbivudine in HBeAg‐positive patients with chronic hepatitis B virus infection
Ching‐Lung Lai, Seng Gee Lim, Nathaniel A. Brown, Xiao‐Jian Zhou, Deborah M. Lloyd, Yin‐Mei Lee, Man‐Fung Yuen, George C. Chao, Maureen W. Myers – 30 August 2004 – Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability. Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical safety profile.